Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Cardiff Oncology Inc (NASDAQ: CRDF) closed at $4.24 down -1.17% from its previous closing price of $4.29. In other words, the price has decreased by -$1.17 from its previous closing price. On the day, 0.89 million shares were traded.
Ratios:
For a deeper understanding of Cardiff Oncology Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.74 and its Current Ratio is at 4.74. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on September 06, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
On December 08, 2021, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $19.Robert W. Baird initiated its Outperform rating on December 08, 2021, with a $19 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 17 ’24 when Levine James E. bought 2,752 shares for $5.42 per share. The transaction valued at 14,905 led to the insider holds 65,316 shares of the business.
Levine James E. bought 2,400 shares of CRDF for $12,000 on Dec 18 ’24. The Chief Financial Officer now owns 67,716 shares after completing the transaction at $5.00 per share. On Dec 16 ’24, another insider, Levine James E., who serves as the Chief Financial Officer of the company, bought 2,564 shares for $3.83 each. As a result, the insider paid 9,820 and bolstered with 62,564 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 408.75 while its Price-to-Book (P/B) ratio in mrq is 4.18.
Stock Price History:
Over the past 52 weeks, CRDF has reached a high of $6.42, while it has fallen to a 52-week low of $1.65. The 50-Day Moving Average of the stock is 9.14%, while the 200-Day Moving Average is calculated to be 40.98%.
Shares Statistics:
A total of 66.52M shares are outstanding, with a floating share count of 59.77M. Insiders hold about 10.14% of the company’s shares, while institutions hold 34.28% stake in the company.
Earnings Estimates
The current market rating for Cardiff Oncology Inc (CRDF) reflects the collective analysis of 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.2 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$0.93 and -$1.03 for the fiscal current year, implying an average EPS of -$0.99. EPS for the following year is -$0.96, with 4.0 analysts recommending between -$0.8 and -$1.32.
Revenue Estimates
A total of 6 analysts have provided revenue estimates for CRDF’s current fiscal year. The highest revenue estimate was $748k, while the lowest revenue estimate was $500k, resulting in an average revenue estimate of $610.67k. In the same quarter a year ago, actual revenue was $488k
